Cost-effectiveness of therapeutic use of safety-engineered syringes in healthcare facilities in India

Bahuguna, P. , Prinja, S., Lahariya, C., Dhiman, R. K., Kumar, M. P., Sharma, V., Aggarwal, A. K., Bhaskar, R., De Graeve, H. and Bekedam, H. (2020) Cost-effectiveness of therapeutic use of safety-engineered syringes in healthcare facilities in India. Applied Health Economics and Health Policy, 18(3), pp. 393-411. (doi: 10.1007/s40258-019-00536-w) (PMID:31741306) (PMCID:PMC7250963)

Abstract

Background: Globally, 16 billion injections are administered each year of which 95% are for curative care. India contributes 25–30% of the global injection load. Over 63% of these injections are reportedly unsafe or deemed unnecessary. Objectives: To assess the incremental cost per quality-adjusted life-year (QALY) gained with the introduction of safety-engineered syringes (SES) as compared to disposable syringes for therapeutic care in India. Methods: A decision tree was used to compute the volume of needle-stick injuries (NSIs) and reuse episodes among healthcare professionals and the patient population. Subsequently, three separate Markov models were used to compute lifetime costs and QALYs for individuals infected with hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Three SES were evaluated—reuse prevention syringe (RUP), sharp injury prevention (SIP) syringe, and syringes with features of both RUP and SIP. A lifetime study horizon starting from a base year of 2017 was considered appropriate to cover all costs and consequences comprehensively. A systematic review was undertaken to assess the SES effects in terms of reduction in NSIs and reuse episodes. These were then modelled in terms of reduction in transmission of blood-borne infections, life-years and QALYs gained. Future costs and consequences were discounted at the rate of 3%. Incremental cost per QALY gained was computed to assess the cost-effectiveness. A probabilistic sensitivity analysis was undertaken to account for parameter uncertainties. Results: The introduction of RUP, SIP and RUP + SIP syringes in India is estimated to incur an incremental cost of Indian National Rupee (INR) 61,028 (US$939), INR 7,768,215 (US$119,511) and INR 196,135 (US$3017) per QALY gained, respectively. A total of 96,296 HBV, 44,082 HCV and 5632 HIV deaths are estimated to be averted due to RUP in 20 years. RUP has an 84% probability to be cost-effective at a threshold of per capita gross domestic product (GDP). The RUP syringe can become cost saving at a unit price of INR 1.9. Similarly, SIP and RUP + SIP syringes can be cost-effective at a unit price of less than INR 1.2 and INR 5.9, respectively. Conclusion: RUP syringes are estimated to be cost-effective in the Indian context. SIP and RUP + SIP syringes are not cost-effective at the current unit prices. Efforts should be made to bring down the price of SES to improve its cost-effectiveness.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Bahuguna, Dr Pankaj
• Authors: Bahuguna, P., Prinja, S., Lahariya, C., Dhiman, R. K., Kumar, M. P., Sharma, V., Aggarwal, A. K., Bhaskar, R., De Graeve, H., and Bekedam, H.
• College/School: College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
• Journal Name: Applied Health Economics and Health Policy
• Publisher: Springer
• ISSN: 1175-5652
• ISSN (Online): 1179-1896
• Published Online: 19 November 2019
• Copyright Holders: Copyright © The Author(s) 2019
• First Published: First published in Applied Health Economics and Health Policy 18(3):393-411
• Publisher Policy: Reproduced under a Creative Commons license